Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : Clown-Free Zone... sorry, no clowns allowed -- Ignore unavailable to you. Want to Upgrade?

To: Trumptown who wrote (288039)	5/24/2004 2:36:00 PM
From: Lucretius	Respond to of 436258

no

To: Trumptown who wrote (288039)	5/24/2004 2:39:36 PM
From: Lucretius	Read Replies (1) \| Respond to of 436258

you sell anythng yet?

To: Trumptown who wrote (288039)	5/25/2004 1:15:59 PM
From: Jane4IceCream	Read Replies (1) \| Respond to of 436258

SR 57....Wake Up man! CCUR in 2.20's Jane

To: Trumptown who wrote (288039)	6/21/2004 10:18:16 AM
From: Pogeu Mahone	Respond to of 436258

Press Release Source: Physiometrix J.M. Dutton & Associates Announces Investment Opinion: Physiometrix Raised To Buy Rating In Update By Dutton & Associates Monday June 21, 9:30 am ET EL DORADO HILLS, Calif.--(BUSINESS WIRE)--June 21, 2004--J.M. Dutton & Associates issues its updated coverage of Physiometrix (Nasdaq:PHYX - News) raising it to a Buy rating and a $4.50 target price. The 5-page report by JM Dutton senior analyst William R. Prather RPh, MD is available at www.jmdutton.com, and from First Call, Bloomberg (JMDA), Zacks, Multex, and other leading financial portals. We are revising our investment rating for Physiometrix from Speculative Buy to Buy after tracking the quality of the roll-out of the Company's Patient State Analyzer (PSA) and peripherals through interviews with representatives of Baxter Health Care's sales team. After interviewing these representatives and speaking with management, we believe the Baxter relationship may be working out, with the Baxter representative being enthusiastic and upbeat on the current version of the PSA and meeting or beating sales quotas. We believe this positive information may be what is needed to initiate appreciation of the Company's valuation and the reason for revising our recommendation. We believe the Company's revenues will mirror our projections, begin escalating in this quarter and hopefully be followed by an increase in the price of the common stock. About Dutton & Associates yada yada